BioSpace News Archive

Today, Primmune Therapeutics announced the close of its Series A financing round with the addition of $4.0 million from Bioqube Ventures, a European life sciences venture capital firm

Biocept, Inc., a leading commercial provider of molecular testing to provide physicians with clinically actionable information to improve patient outcomes, announces that President and CEO Michael W. Nall has issued the following letter to stockholders:

Rezolute, Inc. (Nasdaq: RZLT), today announced the initiation of dosing in a Phase 1 first-in-human clinical study of RZ402, an investigational oral plasma kallikrein inhibitor (PKI), for the treatment of diabetic macular edema (DME).

Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) referred to as “Cipla” today announced that it will participate at the 39th Annual J.P. Morgan Healthcare Conference, which is the largest healthcare investment symposium in the industry.

Netcapital Inc. (OTC: NCPL) announced it will partner with C-Reveal Therapeutics to advance the company’s patent pending approach to exposing tumors to immune responses and therapies

Simulations Plus, Inc. (Nasdaq: SLP), today announced that it has entered into a new funded collaboration with a large pharmaceutical company to develop machine learning models and enhance physiologically based pharmacokinetics / pharmacodynamics (PBPK/PD) approaches for potential treatments of pulmonary infections.

Cohen Veterans Bioscience, a non-profit dedicated to fast-tracking the development of diagnostic tests and personalized therapeutics for the millions of Veterans and civilians who suffer the devastating effects of trauma-related brain disorders, is pleased to announce the appointment of Dr. Dave DeMarco to its Board of Directors.

Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that it has successfully concluded its VenoValve Pre-IDE meeting with the U.S. Food and Drug Administration .

Neogen Corporation (NASDAQ: NEOG) announced today that it has launched a quicker, easier test to detect aflatoxin M1, a known cancer-causing toxin of concern to the global dairy industry.

Monarch Biosciences, Inc. (MonarchBio), a California-based life sciences company, announced today that it has recently received Notices of Allowance from the U.S. Patent and Trademark Office (USPTO) for the following U.S. patent applicat